Every FDA-Approved Antiviral Peptide Drug

Enfuvirtide

4 approved drugs

Four peptide or peptide-derived antiviral drugs have reached regulatory approval: one for HIV, two for hepatitis C, and one for hepatitis D.

Cooper & Bhatt, Drugs, 2004; Kang & Syed, Drugs, 2020

Cooper & Bhatt, Drugs, 2004; Kang & Syed, Drugs, 2020

View as image

The peptide therapeutics pipeline includes hundreds of candidates for infectious disease, but the number that have reached regulatory approval is small enough to list completely. Four antiviral drugs based on peptide structures have been approved by the FDA or EMA: enfuvirtide (HIV, 2003), boceprevir (HCV, 2011), telaprevir (HCV, 2011), and bulevirtide (HDV, 2020). Each represents a different strategy for using peptide chemistry against viral infection: fusion inhibition, protease inhibition, and entry blockade. Two have already been withdrawn from the market. The complete list reveals both the promise and the practical challenges of antiviral peptide drug development.

1. Enfuvirtide (Fuzeon) - HIV Fusion Inhibitor

Approved: March 13, 2003 (FDA) | Status: Available but rarely used | Class: True peptide (36 amino acids)

Enfuvirtide was the first peptide-based antiviral drug to receive FDA approval and remains the only full-length peptide among the approved antiviral agents. It is a synthetic 36-amino acid peptide that mimics a portion of the HIV-1 gp41 transmembrane glycoprotein. By binding to the heptad repeat 1 (HR1) region of gp41, enfuvirtide prevents the conformational change required for viral-host cell membrane fusion, blocking HIV entry into CD4+ T cells.^[1]

Cooper and Bhatt (2004) characterized enfuvirtide as a case study in clinical peptide antiviral development, demonstrating proof-of-concept that targeting the viral fusion machinery with a peptide could suppress viral replication in treatment-experienced patients. In clinical trials, adding enfuvirtide to optimized background therapy reduced HIV-1 RNA by approximately 1.5 log10 copies/mL more than background therapy alone at 24 weeks.

The drug's limitations became apparent quickly. Enfuvirtide requires twice-daily subcutaneous injections, and injection site reactions (pain, induration, erythema, nodules) affected up to 98% of patients in clinical trials. Manufacturing the 36-residue peptide at scale was technically demanding and expensive, with annual treatment costs exceeding $25,000. Resistance mutations in gp41 emerged in some patients. These factors restricted enfuvirtide to salvage therapy for treatment-experienced patients with limited options.

Research into optimizing enfuvirtide's structure continues. Stocks et al. (2021) characterized both native and hydrocarbon-stapled enfuvirtide conformations, exploring whether structural modifications could improve stability and potency.^[2] The fusion inhibitor concept that enfuvirtide validated has also been extended beyond HIV to pan-coronavirus fusion inhibitors targeting the conserved HR1 domain across human coronaviruses.^[3]

2. Boceprevir (Victrelis) - HCV Protease Inhibitor

Approved: May 13, 2011 (FDA) | Status: Withdrawn 2015 | Class: Peptidomimetic

Boceprevir was a peptidomimetic inhibitor of the hepatitis C virus NS3/4A serine protease, an enzyme essential for HCV polyprotein processing and viral replication. Unlike enfuvirtide, boceprevir was not a true peptide but a small molecule designed to mimic the natural peptide substrate of the protease. It contained a ketoamide warhead that formed a reversible covalent bond with the catalytic serine residue of NS3.

Boceprevir was approved for use in combination with peginterferon alfa and ribavirin for the treatment of chronic HCV genotype 1 infection. In the SPRINT-2 trial, the addition of boceprevir to standard therapy increased sustained virologic response (SVR) rates from 38% (standard therapy alone) to 63-66% (boceprevir-containing regimens) in previously untreated patients.

Despite this improvement, boceprevir's clinical life was brief. The drug required three-times-daily dosing with food, had a significant side effect burden (anemia, dysgeusia, neutropenia), and was limited to HCV genotype 1. Within two years of boceprevir's approval, second-generation direct-acting antivirals (sofosbuvir, simeprevir, and later combination regimens) achieved SVR rates exceeding 95% with fewer side effects and shorter treatment duration. Merck voluntarily withdrew Victrelis from the market in 2015.

Boceprevir and telaprevir represent an instructive case in peptide drug development: technically successful drugs that were rapidly superseded by better molecules targeting the same disease.

3. Telaprevir (Incivek) - HCV Protease Inhibitor

Approved: May 23, 2011 (FDA) | Status: Discontinued 2014 | Class: Peptidomimetic

Telaprevir, approved just 10 days after boceprevir, was a structurally related peptidomimetic NS3/4A protease inhibitor with a different chemical warhead (alpha-ketoamide). It was also approved for chronic HCV genotype 1 in combination with peginterferon and ribavirin.

Telaprevir demonstrated slightly higher SVR rates than boceprevir in some comparisons (approximately 75% in treatment-naive patients in the ADVANCE trial), but came with a more severe side effect profile. Skin rash occurred in approximately 56% of telaprevir-treated patients, with severe rash (including Stevens-Johnson syndrome in rare cases) requiring treatment discontinuation in about 6%. Anemia, pruritus, and anorectal discomfort were also common.

Vertex Pharmaceuticals discontinued Incivek in October 2014, less than three and a half years after approval. Like boceprevir, telaprevir was rendered obsolete by the revolution in HCV treatment led by interferon-free, all-oral direct-acting antiviral regimens that achieved near-universal cure rates with minimal side effects.

The rapid rise and fall of boceprevir and telaprevir contains a lesson for peptide drug development: first-in-class approval does not guarantee commercial survival when the therapeutic landscape can shift within a few years.

4. Bulevirtide (Hepcludex) - HDV Entry Inhibitor

Approved: July 2020 (EMA conditional approval) | Status: Active, expanding indications | Class: Lipopeptide (47 amino acids)

Bulevirtide is the most recent and currently the most clinically relevant antiviral peptide drug. It is a myristoylated synthetic lipopeptide of 47 amino acids derived from the pre-S1 domain of the hepatitis B virus (HBV) large surface antigen. Bulevirtide blocks viral entry by binding to the sodium taurocholate co-transporting polypeptide (NTCP) receptor on hepatocytes, the receptor that both HBV and hepatitis D virus (HDV) use to enter liver cells.^[4]

HDV is a defective virus that requires HBV surface antigens for its viral envelope and therefore only infects people already carrying HBV. Chronic HDV co-infection accelerates liver disease progression, with 70% of co-infected patients developing cirrhosis within 5 to 10 years. Before bulevirtide, there was no approved treatment specifically targeting HDV.

Phase 3 clinical data established bulevirtide's efficacy. The MYR301 trial demonstrated that bulevirtide monotherapy (2 mg subcutaneously once daily for 48 weeks) achieved undetectable HDV RNA in 45-48% of patients, compared to 2% in the no-treatment control group. Combination with peginterferon alfa-2a produced even higher response rates. ALT normalization, indicating reduced liver inflammation, occurred in the majority of responders.^[5]

Wedemeyer et al. (2024) reported long-term follow-up data showing that bulevirtide monotherapy maintained virologic suppression through 96 weeks of treatment, with a favorable safety profile. The most common adverse events were injection site reactions and asymptomatic bile salt elevation (expected given NTCP inhibition).^[6]

Bulevirtide received conditional marketing authorization from the EMA in July 2020 and has been granted breakthrough therapy designation by the FDA. Regulatory review for full FDA approval is ongoing. Its success demonstrates that peptide drugs can fill therapeutic gaps where no other treatment class has succeeded.

Comparing the Four Drugs

Two patterns emerge from this table. First, the true peptide drugs (enfuvirtide, bulevirtide) target surface interactions (fusion, entry) where peptides can directly mimic protein-protein binding interfaces. The peptidomimetics (boceprevir, telaprevir) targeted an enzymatic active site, a role where small molecules ultimately proved more practical. Second, the drugs that survived are those targeting viral mechanisms where no superior alternative emerged. Enfuvirtide remains available because it targets a unique mechanism. Bulevirtide is thriving because it is the only approved HDV treatment. The HCV protease inhibitors were displaced precisely because alternative approaches (nucleotide polymerase inhibitors, NS5A inhibitors) proved superior.

What This List Tells Us About Peptide Antivirals

The complete list of approved antiviral peptide drugs is short for reasons that apply broadly to peptide therapeutics. Peptides face delivery challenges: none of the four drugs achieved oral bioavailability, and injection requirements limit patient acceptance. Peptides face stability challenges: enzymatic degradation restricts systemic half-life. Peptides face manufacturing challenges: large-scale synthesis of 36 to 47-residue peptides is more complex and costly than small molecule production.

The pipeline for next-generation antiviral peptides is addressing these limitations. Pan-coronavirus fusion inhibitors derived from the enfuvirtide concept have demonstrated broad-spectrum activity against SARS-CoV-2 and its variants, plus HIV-1, HIV-2, and other enveloped viruses.^[3] Stapled peptides, lipopeptide conjugates, and long-acting formulations are in development to improve pharmacokinetics. Intranasal and inhaled delivery routes are being explored for respiratory viruses.

The four approved drugs prove that peptides can work as antivirals. The two withdrawals prove that working is not enough: peptide antivirals must also offer advantages that simpler drug classes cannot match. Bulevirtide's success, built on targeting an unmet need with a mechanism only a peptide can exploit, may be the model for future antiviral peptide approvals.

The Bottom Line

Four antiviral peptide or peptide-derived drugs have reached regulatory approval: enfuvirtide (HIV fusion inhibitor, 2003), boceprevir and telaprevir (HCV protease inhibitors, both 2011), and bulevirtide (HDV entry inhibitor, 2020). The HCV drugs were withdrawn within 4 years as superior alternatives emerged. Enfuvirtide remains available but rarely used due to injection burden. Bulevirtide is the most clinically active, achieving HDV RNA suppression in 45-48% of patients as the first approved treatment for chronic hepatitis D. The pattern across all four drugs: peptide antivirals succeed when they target viral mechanisms where peptide chemistry offers unique advantages and no simpler alternative exists.

Frequently Asked Questions

How many FDA approved antiviral peptide drugs are there?

Four antiviral drugs based on peptide structures have been approved by the FDA or EMA: enfuvirtide (2003, HIV), boceprevir (2011, HCV), telaprevir (2011, HCV), and bulevirtide (2020, HDV). Two of these (boceprevir and telaprevir) have been withdrawn from the market. Only enfuvirtide and bulevirtide are currently available, with bulevirtide being the most actively prescribed.

What was the first antiviral peptide drug?

Enfuvirtide (brand name Fuzeon) was the first peptide-based antiviral drug, receiving FDA approval on March 13, 2003. It is a 36-amino acid synthetic peptide that blocks HIV-1 from fusing with host cell membranes by targeting the gp41 transmembrane glycoprotein. It was also the first drug in the fusion inhibitor class and proved that peptides could serve as effective antiviral agents.

Why were boceprevir and telaprevir withdrawn?

Both drugs were voluntarily withdrawn by their manufacturers after being rendered clinically obsolete by second-generation direct-acting antivirals. Sofosbuvir-based regimens approved in 2013-2014 achieved sustained virologic response rates exceeding 95% with shorter treatment duration, fewer side effects, and broader genotype coverage than boceprevir or telaprevir could offer. Telaprevir was discontinued in October 2014 and boceprevir in 2015.

Is bulevirtide FDA approved?

Bulevirtide received conditional marketing authorization from the European Medicines Agency (EMA) in July 2020 for the treatment of chronic hepatitis D in adults. The FDA granted breakthrough therapy designation to bulevirtide, and regulatory review for full FDA approval is ongoing. It is available in Europe and several other regions. It is the first and currently only approved treatment specifically targeting hepatitis D virus infection.

Why are there so few approved antiviral peptide drugs?

Peptide drugs face three major challenges in antiviral development: poor oral bioavailability (all four approved agents require injection), enzymatic degradation limiting systemic half-life, and complex manufacturing at scale. Additionally, for many viral infections, small molecule drugs have proven more practical and cost-effective. Peptide antivirals tend to succeed when they target protein-protein interactions that small molecules cannot efficiently disrupt, as with viral fusion and receptor-mediated entry.

What antiviral peptide drugs are in clinical trials?

Next-generation antiviral peptides in development include pan-coronavirus fusion inhibitors targeting the HR1 domain (effective against SARS-CoV-2 and variants), long-acting enfuvirtide analogs with improved pharmacokinetics, and intranasal peptide formulations for respiratory viruses. Stapled peptides and lipopeptide conjugates are being explored to improve stability and reduce dosing frequency compared to first-generation agents.